SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as anticipation builds for the imminent Phase 3 REGAL trial readout for its AML cancer drug, GPS, with the community highly optimistic about "curative" outcomes and a potential buyout given strong clinical signals and recent comments from the CEO. The stock is reaching multi-year highs amid heavy call option activity, suggesting investors are pricing in a successful outcome and a potential short squeeze.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as its inclusion in a White House-backed eVTOL program for U.S. operations, coupled with the launch of Uber Air in Dubai, fuels community discussion around its accelerated path to commercial air taxi services and robust partnerships.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is trending amidst intense volatility driven by escalating geopolitical tensions in the Middle East, with ongoing conflict impacting oil supply routes and leading to wildly fluctuating crude prices. The community is sharply divided between those anticipating a significant short squeeze in oil-related stocks and others warning of a rapid correction, especially following a recent stock offering.

Vail Resorts, Inc. is a holding company, which engages in the operation of mountain resorts. It operates through the following segments: Mountain, Lodging, and Real Estate. The Mountain segment covers the operation of mountain resorts or ski areas, and related activities. The Lodging segment includes ownership of hotels, RockResorts, NPS concessionaire properties, condominium management, Colorado resort ground transportation operations, and mountain resort golf operations. The Real Estate segment owns, develops, and sells real estate in and around its resort communities. The company was founded by Pete Seibert and Earl Eaton in March 1957 and is headquartered in Broomfield, CO.

Vail Resorts Inc.

Vail Resorts is trending after reporting Q2 earnings and cutting fiscal 2026 guidance, primarily due to historically low snowfall in the Rockies. The community is actively debating management's strategy and the long-term viability of its Epic Pass model, with many questioning the stock's valuation and calling for a dividend cut.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is actively trending amid escalating geopolitical tensions involving Iran, with many speculating on significant market volatility and a potential surge for the ETF. Conversely, a strong contingent views UVXY as a 'widowmaker' ETF, advocating for shorting its spikes due to its inherent decay and structure.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is seeing a massive surge in trading volume and share price, driven by a recently announced $40 million private placement. The community is actively debating the implications of this offering, with some anticipating a short squeeze and others questioning the sustainability of its current valuation compared to the offering price.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amidst strong anticipation for its Bankable Feasibility Study update, which many in the community believe will significantly re-rate the value of its heavy rare earth Tanbreez project. Geopolitical tensions are intensifying the conversation around the strategic importance of domestic critical mineral supply chains, positioning CRML as a key player in a sector poised for potential revaluation.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the Design Automation and Design IP segments. The Design Automation segment includes silicon design, verification of products and services, and Ansys products, and system integration of products and services. The Design IP segment refers to interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services that serve companies primarily in the semiconductor and electronics industries. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

Synopsys is trending following NVIDIA's strategic investment and expanded partnership for AI engineering, though recent earnings, despite beating adjusted estimates, triggered a sell-off due to mixed guidance and concerns over organic growth and China exposure. The community remains divided, with many viewing the dip as a buying opportunity given Synopsys' critical role in chip design, while others express confusion over the volatility.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors anticipate details on its midsize vehicle and a path to profitability at an upcoming Investor Day, while recent mixed earnings showing revenue growth alongside widening losses, significant workforce layoffs, and record-low stock prices intensify community debate over its financial health and future in the luxury EV sector.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics is trending due to the highly anticipated PDUFA action date for its dry eye disease drug, reproxalap, creating a fiercely polarized discussion where bulls anticipate approval based on draft label discussions and rapid efficacy, while bears foresee a third Complete Response Letter citing prior rejections and concerns over trial data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: Nanovibronix (NASDAQ:FEED) Major Shareholder Purchases 240,000 Shares of Stock

Nanovibronix, Inc. (NASDAQ:FEED - Get Free Report) major shareholder Christian Michael Glibert purchased 240,000 shares of the firm's stock in a transaction dated Wednesday, January 14th. The stock...

<ul class="summary-bullets"><li>The agreement is aimed at distributing Texas-based ENvue’s recently launched over-the-counter reusable ENFit Syringes product line nationwide.&nbsp;</li><li>The syringes were launched earlier this month and are designed to meet both feeding and medication delivery clinical needs.&nbsp;</li><li>The new deal would utilize U-Deliver’s digital and wholesale channels to broaden access to the syringes launched earlier this month.&nbsp; &nbsp;</li></ul>Shares of ENvue Medical, Inc. (FEED) jumped 138% on Wednesday after the company announced a distribution agreement with enteral feeding supplies provider U-Deliver.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/28/3227664/0/en/ENvue-Medical-Signs-Strategic-Partnership-Agreement-with-U-Deliver-for-U-S-Distribution-of-Over-the-Counter-Reusable-ENFit-Syringe-Line.html">agreement</a> is aimed at distributing Texas-based ENvue’s recently launched over-the-counter reusable ENFit Syringes product line nationwide through non-acute care channels. The deal would utilize U-Deliver’s digital and wholesale channels to broaden access to the syringes launched earlier this month.<h2 class="st-heading-2">About ENVue Syringes</h2>ENvue’s ENFit Syringes are currently available through U-Deliver’s website, Amazon storefront, and wholesale channels in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes. These syringes, designed for reuse for up to seven days or 20 uses, do not require a prescription. They are also designed to meet both feeding and medication delivery clinical needs.ENVue was formerly called NanoVibronix. The company switched names to reflect its focus on the ENvue feeding-tube placement system, which it gained access to with the acquisition of privately-held ENvue Medical Holdings Corp in February 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FEED rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.A Stocktwits user said that they sold their shares in the company for a 20% profit.<stembedurl>https://www.stocktwits.com/NathanN23/message/643168472</stembedurl>Another user, however, highlighted the company’s “insanely low” market cap, adding that it is less than someone's net worth.<stembedurl>https://www.stocktwits.com/Shorting_BTC_Since_2009/message/643160653</stembedurl>Yet another user predicted upcoming dilution efforts.<stembedurl>https://www.stocktwits.com/Biotoneten/message/643159817</stembedurl><a href="https://stocktwits.com/symbol/FEED">FEED stock</a> has lost about 94% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cvna-shares-in-spotlight-after-gotham-city-research-highlights-red-flags/cmygaQtR400">CVNA Shares In Spotlight After Gotham City Research Highlights Red Flags — What Does The Street Think?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is FEED Stock Soaring Over 130% Today?

ENvue Medical announced a distribution agreement with enteral feeding supplies provider U-Deliver. 

Equity

ENvue Medical announced a distribution agreement with enteral feeding supplies provider U-Deliver. 


This MedTech Stock Just Surged 81% on a Distribution Deal You Didn't See Coming

The home healthcare market continues to expand as patients and caregivers seek reliable medical solutions outside traditional hospital settings. Enteral feeding&#8212;delivering nutrition directly to the gastrointestinal tract&#8212;represents a critical segment of this market, with millions of Americans relying on tube feeding for daily nutrition and medication delivery. As care increasingly shifts from acute facilities to home environments, demand is growing for accessible, affordable products that maintain clinical standards.Shares of ENvue Medical, Inc. (NASDAQ: FEED) are soaring ...

ENvue Medical, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.

Current Price	$1.93
Prev Close	$2.01
Open	$1.93
Dividend Yield	0.00%
50-Day Moving Average	$2.30
Beta	0.67
Avg. Volume	3.94M
PE Ratio	-0.02

52-Week High	$162.50
52-Week Low	$0.99
Market Capitalization	$2.19M
EPS (Annual)	-$137.30
Price to Book	0.05
Revenue Per Employee	$82,516.13

FEED
ENvue Medical, Inc. Common Stock

Feed

News

Sentiment

Fundamentals

Info

Latest FEED News

FEEDENvue Medical, Inc. Common Stock